<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="00b7b683-69a7-48cc-8286-67288e91c859"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>DESOXIMETASONE CREAM USP, 0.25%</title>
   <effectiveTime value="20250307"/>
   <setId root="4ad6c159-4daa-4a33-8db6-351b5263323d"/>
   <versionNumber value="10"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="600093611" root="1.3.6.1.4.1.519.1"/>
            <name>Padagis Israel Pharmaceuticals Ltd</name>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="bd862e19-ad16-4955-a82c-587cb2186a01"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20170111"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="45802-495" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Desoximetasone</name>
                        <formCode code="C28944" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CREAM"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Desoximetasone</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="2.5"/>
                              <denominator unit="g" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4E07GXB7AU" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Desoximetasone</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="4E07GXB7AU" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Desoximetasone</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="P9BC99461E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ALUMINUM MONOSTEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2DMT128M1S" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CETOSTEARYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="0RE8K4LNJS" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ISOPROPYL MYRISTATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="884C3FA9HE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LANOLIN ALCOHOLS</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="T5L8T28FGP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MINERAL OIL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="I9O0E3H2ZE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PARAFFIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4T6H12BN9U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PETROLATUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="g" value="15"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C42794" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TUBE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="45802-495-35" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20061116"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="g" value="60"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C42794" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TUBE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="45802-495-37" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20061024"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA076510" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20061024"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38304" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TOPICAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="i4i_section_id_fb3a353a-57ae-47a7-8d85-6341faf72405">
               <id root="9d303c3e-db06-4099-a405-a2fe7c3e265f"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">For Dermatologic Use Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Not For Use In Eyes</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
               </text>
               <effectiveTime value="20170111"/>
            </section>
         </component>
         <component>
            <section ID="i4i_description_id_c01f86aa-47ee-4fce-bf73-ae5769eee76d">
               <id root="184e4899-a7e0-4fca-b5df-c15863a2e11d"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>Desoximetasone Cream USP, 0.25% contains the active synthetic corticosteroid desoximetasone. The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and anti-pruritic agents.</paragraph>
                  <paragraph>Each gram of Desoximetasone Cream USP, 0.25% contains 2.5 mg of desoximetasone in an emollient cream consisting of aluminum monostearate, cetostearyl alcohol, isopropyl myristate, lanolin alcohols, magnesium stearate, mineral oil, paraffin wax, purified water, and white petrolatum.</paragraph>
                  <paragraph>The chemical name of desoximetasone is Pregna-1,4-diene-3,20-dione,9-fluoro-11,21-dihydroxy-16-methyl-,(11β,16α)-. Desoximetasone has the molecular formula C<sub>22</sub>H<sub>29</sub>FO<sub>4</sub> and a molecular weight of 376.47. The CAS Registry Number is 382-67-2. The chemical structure is:</paragraph>
                  <renderMultiMedia ID="id9956113" referencedObject="ID_92f49057-0825-4501-bf66-df3e34dac2e9"/>
               </text>
               <effectiveTime value="20230809"/>
               <component>
                  <observationMedia ID="ID_92f49057-0825-4501-bf66-df3e34dac2e9">
                     <text>structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_clinical_pharmacology_id_ecb31404-7960-416a-80ac-bc584f155772">
               <id root="3b648316-a513-4214-a75a-e5141590f578"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. </paragraph>
               </text>
               <effectiveTime value="20170111"/>
               <component>
                  <section ID="i4i_pharmacokinetics_id_1b286b18-4408-49aa-b324-5064701d27c5">
                     <id root="f26a73eb-4419-40f3-8f77-adbdefb97355"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>Pharmacokinetics -</title>
                     <text>
                        <paragraph>The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. </paragraph>
                        <paragraph>Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses.</paragraph>
                        <paragraph>Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.</paragraph>
                        <paragraph>Pharmacokinetic studies in men with desoximetasone cream 0.25% with tagged desoximetasone showed a total of 5.2% ± 2.9% excretion in urine (4.1% ± 2.3%) and feces (1.1% ± 0.6%) and no detectable level (limit of sensitivity: 0.005 µg/mL) in the blood when it was applied topically on the back followed by occlusion for 24 hours. Seven days after application, no further radioactivity was detected in urine or feces. The half-life of the material was 15 ± 2 hours (for urine) and 17 ± 2 hours (for feces) between the third and fifth trial day. Studies with other similarly structured steroids have shown that predominant metabolite reaction occurs through conjugation to form the glucuronide and sulfate ester.</paragraph>
                     </text>
                     <effectiveTime value="20170111"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_indications_id_afa08624-78ad-4533-a0f9-d12e6767d5b8">
               <id root="06841b59-7f68-9c3e-fd36-7eef3da32964"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Desoximetasone Cream USP, 0.25% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.</paragraph>
               </text>
               <effectiveTime value="20070109"/>
            </section>
         </component>
         <component>
            <section ID="i4i_contraindications_id_b56b31e9-b113-4605-9abb-6f99be132f69">
               <id root="90b1ef8b-5633-01fe-4965-a768003733dc"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.</paragraph>
               </text>
               <effectiveTime value="20070109"/>
            </section>
         </component>
         <component>
            <section ID="i4i_warnings_id_1b41a27b-60ed-4a4e-bba7-c939f658e849">
               <id root="c986662a-4dac-a281-1cff-4097a94774c0"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <paragraph>Desoximetasone Cream USP, 0.25% is not for ophthalmic use.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Keep out of reach of children.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20070109"/>
            </section>
         </component>
         <component>
            <section ID="i4i_precautions_id_prec">
               <id root="0425e8d6-aa3a-4928-9d18-b48b96c33742"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20170111"/>
               <component>
                  <section ID="i4i_precautions_general_id_6d87c42e-6b2a-4465-aacf-903fd1131f64">
                     <id root="749edc99-1076-4884-bad6-d70c66416f76"/>
                     <code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <title>General -</title>
                     <text>
                        <paragraph>Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. </paragraph>
                        <paragraph>Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid. Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.</paragraph>
                        <paragraph>Pediatric patients may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity. (See <content styleCode="bold">
                              <linkHtml href="#i4i_pediatric_use_id_pediatric">PRECAUTIONS – Pediatric Use</linkHtml>
                           </content>). If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.</paragraph>
                        <paragraph>In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.</paragraph>
                     </text>
                     <effectiveTime value="20170111"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_info_patients_id_247018cf-c05e-4206-9121-a63af9519515">
                     <id root="691619bb-66a1-4421-971c-4b51fdbbda2e"/>
                     <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>Information for Patients</title>
                     <text>
                        <paragraph>Patients using topical corticosteroids should receive the following information and instructions:</paragraph>
                        <list listType="ordered">
                           <item>
                              <caption>1.</caption>This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes. </item>
                           <item>
                              <caption>2.</caption>Patients should be advised not to use this medication for any disorder other than for which it was prescribed. </item>
                           <item>
                              <caption>3.</caption>The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician. </item>
                           <item>
                              <caption>4.</caption>Patients should report any signs of local adverse reactions, especially under occlusive dressing. </item>
                           <item>
                              <caption>5.</caption>Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.</item>
                        </list>
                     </text>
                     <effectiveTime value="20150609"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_lab_tests_id_a33c8924-0da9-4f30-9098-9b0beaf1ca8f">
                     <id root="a9c2b3fb-afea-4757-b473-4754a577d223"/>
                     <code code="34075-2" codeSystem="2.16.840.1.113883.6.1" displayName="LABORATORY TESTS SECTION"/>
                     <title>Laboratory Tests</title>
                     <text>
                        <paragraph>The following tests may be helpful in evaluating the HPA axis suppression: </paragraph>
                        <paragraph>Urinary free cortisol test </paragraph>
                        <paragraph>ACTH stimulation test</paragraph>
                     </text>
                     <effectiveTime value="20130709"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_carcinogenesis_mutagenesis_fertility_id_688ce928-7e91-4a9e-ab62-6ac84137f08a">
                     <id root="435637ab-3a99-452c-b8ec-21def0d70ba6"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>Carcinogenesis, Mutagenesis, Impairment of Fertility -</title>
                     <text>
                        <paragraph>Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids.</paragraph>
                        <paragraph>Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results. Desoximetasone did not show potential for mutagenic activity <content styleCode="italics">in vitro</content> in the Ames microbial mutagen test with or without metabolic activation.</paragraph>
                     </text>
                     <effectiveTime value="20130709"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_pregnancy_id_37e00e6e-3835-4704-b7a3-133087ee3dfd">
                     <id root="51dc12e7-75db-4a38-b30c-26e003bde584"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>Pregnancy:</title>
                     <effectiveTime value="20170111"/>
                     <component>
                        <section ID="i4i_teratogenic_id_6b1d1ef2-b187-455c-845e-54a9c00bf5b1">
                           <id root="6c03d1f1-a8eb-4f07-9a57-8e9d95d9083a"/>
                           <code code="34077-8" codeSystem="2.16.840.1.113883.6.1" displayName="TERATOGENIC EFFECTS SECTION"/>
                           <title>
                              <content styleCode="bold">Teratogenic Effects:</content>
                           </title>
                           <effectiveTime value="20170111"/>
                           <component>
                              <section ID="i4i_pregnancy_C_id_4c8ea3e0-4868-49c0-abf9-2f0320228fa4">
                                 <id root="21586466-26c3-4e09-b885-72af62d161a2"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>
                                    <content styleCode="bold">Pregnancy Category C -</content>
                                 </title>
                                 <text>
                                    <paragraph>Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals.</paragraph>
                                    <paragraph>Desoximetasone has been shown to be teratogenic and embryotoxic in mice, rats, and rabbits when given by subcutaneous or dermal routes of administration in doses 3 to 30 times the human dose of Desoximetasone Cream USP, 0.25%.</paragraph>
                                    <paragraph>There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, Desoximetasone Cream USP, 0.25% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.</paragraph>
                                 </text>
                                 <effectiveTime value="20170111"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="i4i_nursing_mothers_id_f3da32bd-1800-4fd8-928b-e9dc196c42d3">
                     <id root="da29a16a-81da-41bb-b0ea-348f16f5d8ad"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>Nursing Mothers -</title>
                     <text>
                        <paragraph>It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.</paragraph>
                     </text>
                     <effectiveTime value="20130709"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_pediatric_use_id_pediatric">
                     <id root="344d2633-ca6a-4324-867d-f63932b4788a"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>Pediatric Use -</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio.</content> HPA axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in pediatric patients include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.</paragraph>
                        <paragraph>Administration of topical corticosteroids to pediatric patients should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of pediatric patients.</paragraph>
                     </text>
                     <effectiveTime value="20130709"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_adverse_effects_id_e08d8989-37be-4ce7-ac55-5e10443716c7">
               <id root="fa1afd53-4be2-441e-af54-9a4bdef20513"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, miliaria</paragraph>
                  <paragraph>In controlled clinical studies, the incidence of adverse reactions was low (0.8%) for desoximetasone cream 0.25%, and included burning, folliculitis and folliculo-pustular lesions.</paragraph>
               </text>
               <effectiveTime value="20070109"/>
            </section>
         </component>
         <component>
            <section ID="i4i_overdosage_id_d00423cd-3531-478b-a593-448df9f66ad6">
               <id root="f7a7b0f5-eee7-455f-a851-1c47d93754d8"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <paragraph>Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see <content styleCode="bold">
                        <linkHtml href="#i4i_precautions_id_prec">PRECAUTIONS</linkHtml>
                     </content>).</paragraph>
               </text>
               <effectiveTime value="20130709"/>
            </section>
         </component>
         <component>
            <section ID="i4i_dosage_admin_id_9a2765aa-8085-4a26-860a-aa05c50d2daf">
               <id root="a94afd08-d464-e33a-be8f-6ac642030a89"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Apply a thin film of Desoximetasone Cream USP, 0.25% to the affected skin areas twice daily. Rub in gently.</paragraph>
               </text>
               <effectiveTime value="20070109"/>
            </section>
         </component>
         <component>
            <section ID="i4i_how_supplied_id_93c9f444-fc4b-45a7-b1bb-77e35b2f7ba6">
               <id root="1d12470a-b1ca-47c4-9a2b-ae51907ff3b2"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>Desoximetasone Cream USP, 0.25% is available as follows:</paragraph>
                  <paragraph>15 g tube (NDC 45802-<content styleCode="bold">495</content>-35)</paragraph>
                  <paragraph>60 g tube (NDC 45802-<content styleCode="bold">495</content>-37)</paragraph>
               </text>
               <effectiveTime value="20070109"/>
            </section>
         </component>
         <component>
            <section ID="i4i_storage_id_afef6369-b2c6-4c4a-95d3-f66d11d3800d">
               <id root="f3bcef64-d8d5-4dbd-9afc-abef42488436"/>
               <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
               <title>STORAGE</title>
               <text>
                  <paragraph>Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature].</paragraph>
                  <paragraph>Manufactured by Padagis<sup>®</sup>
                     <br/>Yeruham, Israel</paragraph>
                  <paragraph>www.padagis.com</paragraph>
                  <paragraph>Rev 02-23</paragraph>
                  <paragraph>3L100 RC PH1</paragraph>
               </text>
               <effectiveTime value="20250307"/>
            </section>
         </component>
         <component>
            <section ID="ID_925b2b35-1196-492c-ad6a-671c9b9b3e32">
               <id root="29158305-5c11-4e2a-995b-47273d56fd31"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>NDC 45802-495-35</paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>Desoximetasone Cream USP, 0.25%</paragraph>
                  <paragraph>For Dermatologic Use Only. Not For Use In Eyes.</paragraph>
                  <paragraph>NET WT 15 g</paragraph>
                  <renderMultiMedia ID="id1035385607" referencedObject="ID_115e93ac-d87b-41d6-b5a2-a530189895a7"/>
                  <paragraph>The following image is a placeholder representing the product identifier that is either affixed or imprinted on the drug package label during the packaging operation.</paragraph>
                  <renderMultiMedia ID="id570246046" referencedObject="ID_294dc812-8455-4a1a-9562-b5c69d068b68"/>
               </text>
               <effectiveTime value="20250307"/>
               <component>
                  <observationMedia ID="ID_115e93ac-d87b-41d6-b5a2-a530189895a7">
                     <text>Desoximetasone Cream USP, 0.25% carton image</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="3l114rcc2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_294dc812-8455-4a1a-9562-b5c69d068b68">
                     <text>serialization-template.jpg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="serialization-template.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>